Mechanism of immunopotentiation by aluminum-containing adjuvants elucidated by the relationship between antigen retention at the inoculation site and the immune response

Stephanie M. Noe, Mark Green, Harm HogenEsch, Stanley L. Hem

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

The relationship between depot formation and immunopotentiation was studied by comparing the retention of antigen at the inoculation site with antibody production in rats. A model 111In-labeled alpha casein (IDCAS) antigen was formulated into four vaccines: IDCAS adsorbed onto either aluminum hydroxide adjuvant (AH) or aluminum phosphate adjuvant (AP); non-adsorbed IDCAS with phosphate-treated AP (PTAP); and IDCAS solution. Gamma scintigraphy showed the order of retention following subcutaneous administration to be: AH adsorbed > AP adsorbed > non-adsorbed with PTAP = solution. The antibody titers followed the order: non-adsorbed with PTAP = AP adsorbed > AH adsorbed ≫ solution. The presence of an aluminum-containing adjuvant was essential for immunopotentiation, but retention of the antigen at the inoculation site was not required.

Original languageEnglish (US)
Pages (from-to)3588-3594
Number of pages7
JournalVaccine
Volume28
Issue number20
DOIs
StatePublished - Apr 30 2010
Externally publishedYes

Fingerprint

Aluminum
Aluminum Hydroxide
adjuvants
aluminum
vaccination
immune response
aluminum phosphate
antigens
Antigens
Phosphates
aluminum hydroxide
phosphates
Caseins
Radionuclide Imaging
Antibody Formation
Vaccines
alpha-casein
scintigraphy
Antibodies
subcutaneous injection

Keywords

  • Aluminum-containing adjuvants
  • Immunopotentiation
  • Retention at inoculation site

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Mechanism of immunopotentiation by aluminum-containing adjuvants elucidated by the relationship between antigen retention at the inoculation site and the immune response. / Noe, Stephanie M.; Green, Mark; HogenEsch, Harm; Hem, Stanley L.

In: Vaccine, Vol. 28, No. 20, 30.04.2010, p. 3588-3594.

Research output: Contribution to journalArticle

@article{e8c98735c1f04dde957333312c5c0056,
title = "Mechanism of immunopotentiation by aluminum-containing adjuvants elucidated by the relationship between antigen retention at the inoculation site and the immune response",
abstract = "The relationship between depot formation and immunopotentiation was studied by comparing the retention of antigen at the inoculation site with antibody production in rats. A model 111In-labeled alpha casein (IDCAS) antigen was formulated into four vaccines: IDCAS adsorbed onto either aluminum hydroxide adjuvant (AH) or aluminum phosphate adjuvant (AP); non-adsorbed IDCAS with phosphate-treated AP (PTAP); and IDCAS solution. Gamma scintigraphy showed the order of retention following subcutaneous administration to be: AH adsorbed > AP adsorbed > non-adsorbed with PTAP = solution. The antibody titers followed the order: non-adsorbed with PTAP = AP adsorbed > AH adsorbed ≫ solution. The presence of an aluminum-containing adjuvant was essential for immunopotentiation, but retention of the antigen at the inoculation site was not required.",
keywords = "Aluminum-containing adjuvants, Immunopotentiation, Retention at inoculation site",
author = "Noe, {Stephanie M.} and Mark Green and Harm HogenEsch and Hem, {Stanley L.}",
year = "2010",
month = "4",
day = "30",
doi = "10.1016/j.vaccine.2010.02.085",
language = "English (US)",
volume = "28",
pages = "3588--3594",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "20",

}

TY - JOUR

T1 - Mechanism of immunopotentiation by aluminum-containing adjuvants elucidated by the relationship between antigen retention at the inoculation site and the immune response

AU - Noe, Stephanie M.

AU - Green, Mark

AU - HogenEsch, Harm

AU - Hem, Stanley L.

PY - 2010/4/30

Y1 - 2010/4/30

N2 - The relationship between depot formation and immunopotentiation was studied by comparing the retention of antigen at the inoculation site with antibody production in rats. A model 111In-labeled alpha casein (IDCAS) antigen was formulated into four vaccines: IDCAS adsorbed onto either aluminum hydroxide adjuvant (AH) or aluminum phosphate adjuvant (AP); non-adsorbed IDCAS with phosphate-treated AP (PTAP); and IDCAS solution. Gamma scintigraphy showed the order of retention following subcutaneous administration to be: AH adsorbed > AP adsorbed > non-adsorbed with PTAP = solution. The antibody titers followed the order: non-adsorbed with PTAP = AP adsorbed > AH adsorbed ≫ solution. The presence of an aluminum-containing adjuvant was essential for immunopotentiation, but retention of the antigen at the inoculation site was not required.

AB - The relationship between depot formation and immunopotentiation was studied by comparing the retention of antigen at the inoculation site with antibody production in rats. A model 111In-labeled alpha casein (IDCAS) antigen was formulated into four vaccines: IDCAS adsorbed onto either aluminum hydroxide adjuvant (AH) or aluminum phosphate adjuvant (AP); non-adsorbed IDCAS with phosphate-treated AP (PTAP); and IDCAS solution. Gamma scintigraphy showed the order of retention following subcutaneous administration to be: AH adsorbed > AP adsorbed > non-adsorbed with PTAP = solution. The antibody titers followed the order: non-adsorbed with PTAP = AP adsorbed > AH adsorbed ≫ solution. The presence of an aluminum-containing adjuvant was essential for immunopotentiation, but retention of the antigen at the inoculation site was not required.

KW - Aluminum-containing adjuvants

KW - Immunopotentiation

KW - Retention at inoculation site

UR - http://www.scopus.com/inward/record.url?scp=77950596439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950596439&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.02.085

DO - 10.1016/j.vaccine.2010.02.085

M3 - Article

C2 - 20211692

AN - SCOPUS:77950596439

VL - 28

SP - 3588

EP - 3594

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 20

ER -